Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
316.40
+2.90 (0.93%)
Jul 7, 2026, 10:54 AM EDT - Market open
Praxis Precision Medicines Employees
Praxis Precision Medicines had 168 employees as of December 31, 2025. The number of employees increased by 52 or 44.83% compared to the previous year.
Employees
168
Change (1Y)
52
Growth (1Y)
44.83%
Revenue / Employee
n/a
Profits / Employee
-$1,943,649
Market Cap
8.82B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 168 | 52 | 44.83% | 168 | 0 |
| Dec 31, 2024 | 116 | 34 | 41.46% | 116 | 0 |
| Dec 31, 2023 | 82 | -27 | -24.77% | 82 | 0 |
| Dec 31, 2022 | 109 | -30 | -21.58% | 109 | 0 |
| Dec 31, 2021 | 139 | 72 | 107.46% | 139 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Corcept Therapeutics | 730 |
| ImmunityBio | 691 |
| Vaxcyte | 507 |
| Halozyme Therapeutics | 423 |
| Mirum Pharmaceuticals | 418 |
| Rhythm Pharmaceuticals | 414 |
| Immunovant | 315 |
| Apogee Therapeutics | 261 |
PRAX News
- 2 hours ago - Praxis Precision, Remagine Labs announce research collaboration and license pact - TheFly
- 3 hours ago - Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor - GlobeNewsWire
- 4 days ago - Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 days ago - Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies - GlobeNewsWire
- 8 days ago - Praxis Precision price target raised to $575 from $510 at Needham - TheFly
- 15 days ago - Praxis Precision granted breakthrough therapy designation for elsunersen - TheFly
- 15 days ago - Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants - GlobeNewsWire
- 19 days ago - Praxis Precision initiated with an Outperform at RBC Capital - TheFly